- Home
- RGR vs MLYS Comparison
RGR vs MLYS Comparison
Compare RGR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGR
- MLYS
- Stock Information
- Founded
- RGR 1949
- MLYS 2019
- Country
- RGR United States
- MLYS United States
- Employees
- RGR N/A
- MLYS N/A
- Industry
- RGR Ordnance And Accessories
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- RGR Industrials
- MLYS Health Care
- Exchange
- RGR Nasdaq
- MLYS Nasdaq
- Market Cap
- RGR 616.8M
- MLYS 1.0B
- IPO Year
- RGR N/A
- MLYS 2023
- Fundamental
- Price
- RGR $35.72
- MLYS $14.80
- Analyst Decision
- RGR
- MLYS Strong Buy
- Analyst Count
- RGR 0
- MLYS 4
- Target Price
- RGR N/A
- MLYS $27.00
- AVG Volume (30 Days)
- RGR 191.8K
- MLYS 903.4K
- Earning Date
- RGR 07-30-2025
- MLYS 08-12-2025
- Dividend Yield
- RGR 1.96%
- MLYS N/A
- EPS Growth
- RGR N/A
- MLYS N/A
- EPS
- RGR 1.83
- MLYS N/A
- Revenue
- RGR $534,561,000.00
- MLYS N/A
- Revenue This Year
- RGR N/A
- MLYS N/A
- Revenue Next Year
- RGR $1.89
- MLYS N/A
- P/E Ratio
- RGR $19.47
- MLYS N/A
- Revenue Growth
- RGR 0.65
- MLYS N/A
- 52 Week Low
- RGR $32.74
- MLYS $8.24
- 52 Week High
- RGR $46.40
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- RGR 41.91
- MLYS 53.41
- Support Level
- RGR $35.53
- MLYS $13.44
- Resistance Level
- RGR $36.36
- MLYS $14.70
- Average True Range (ATR)
- RGR 0.70
- MLYS 0.67
- MACD
- RGR -0.06
- MLYS 0.12
- Stochastic Oscillator
- RGR 11.35
- MLYS 99.44
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.